These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28881928)

  • 1. Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv158-iv161. PubMed ID: 28881928
    [No Abstract]   [Full Text] [Related]  

  • 2. Appendix 8: Metastatic non-small-cell lung cancer (2): eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv162-iv164. PubMed ID: 28881929
    [No Abstract]   [Full Text] [Related]  

  • 3. Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv157. PubMed ID: 28881927
    [No Abstract]   [Full Text] [Related]  

  • 4. Appendix 3: Soft tissue sarcoma: MCBS eUpdate published online 5 May 2017(www.esmo.org/Guidelines/Sarcoma-and-GIST).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv147-iv148. PubMed ID: 28881924
    [No Abstract]   [Full Text] [Related]  

  • 5. Appendix 1: Renal cell carcinoma: MCBS eUpdate published online 10 April 2017(www.esmo.org/Guidelines/Genitourinary-Cancers).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv143-iv144. PubMed ID: 28881922
    [No Abstract]   [Full Text] [Related]  

  • 6. Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv145-iv146. PubMed ID: 28881923
    [No Abstract]   [Full Text] [Related]  

  • 7. Onartuzumab ineffective in non-small-cell lung cancer.
    Brower V
    Lancet Oncol; 2017 Feb; 18(2):e66. PubMed ID: 28017663
    [No Abstract]   [Full Text] [Related]  

  • 8. [Consolidation therapy in advanced non-small cell lung cancer].
    Duchnowska R
    Pneumonol Alergol Pol; 2010; 78(6):439-44. PubMed ID: 21077036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage therapy in patients with advanced non-small cell lung cancer.
    Bedano PM; Hanna NH
    J Thorac Oncol; 2006 Jul; 1(6):582-7. PubMed ID: 17409922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appendix 1: Cancer of the Prostate: eUpdate published online 28 September 2017 (http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate).
    ESMO Guidelines Committee
    Ann Oncol; 2018 Oct; 29(Suppl 4):iv256. PubMed ID: 30285212
    [No Abstract]   [Full Text] [Related]  

  • 11. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.
    Carser JE; Summers YJ
    J Thorac Oncol; 2006 Nov; 1(9):1040-1. PubMed ID: 17409992
    [No Abstract]   [Full Text] [Related]  

  • 12. American Society of Clinical Oncology Annual Meeting 2013.
    Yaqub F
    Lancet Respir Med; 2013 Jul; 1(5):360-1. PubMed ID: 24429195
    [No Abstract]   [Full Text] [Related]  

  • 13. [TRUST study: general practice relevant data on erlotinib in NSCLC].
    Knabl A
    Wien Med Wochenschr; 2007; 157(21-22):579-80. PubMed ID: 18157598
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
    Gandara DR; Wakelee H; Calhoun R; Jablons D
    J Thorac Oncol; 2007 Jul; 2(7 Suppl 3):S125-7. PubMed ID: 17603308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
    J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
    Pérol M
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
    [No Abstract]   [Full Text] [Related]  

  • 17. Onartuzumab in lung cancer: the fall of Icarus?
    Rolfo C; Van Der Steen N; Pauwels P; Cappuzzo F
    Expert Rev Anticancer Ther; 2015 May; 15(5):487-9. PubMed ID: 25818471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
    Sandler A
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations.
    Giuliani J; Remo A; Bonetti A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):5-8. PubMed ID: 27830967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.